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Abstract
Background: Mobile devices are gaining a rising number of users in all countries around the globe. 
Novel solutions to diagnose patients with out-of-hospital onset of arrhythmic symptoms can be easily 
used to record such events, but the effectiveness of these devices remain unknown.
Methods: In a group of 100 consecutive patients of an academic cardiology care center (mean age  
68 ± 14.2 years, males: 66%) a standard 12-lead electrocardiogram (ECG) and a Kardia Mobile (KM) 
record were registered. Both versions were assessed by three independant groups of physicians.
Results: The analysis of comparisons for standard ECG and KM records showed that the latter is of 
lower quality (p < 0.001). It was non-inferior for detection of atrial fibrillation and atrial flutter, showed 
weaker rhythm detection in pacemaker stimulation (p = 0.008), and was superior in sinus rhythm 
detection (p = 0.02), though. The sensitivity of KM to detect pathological Q-wave was low compared 
to specificity (20.6% vs. 93.7%, respectively, p < 0.001). Basic intervals measured by the KM device, 
namely PQ, RR, and QT were significantly different (shorter) than those observed in the standard 
ECG method (160 ms vs. 180 ms [p < 0.001], 853 ms vs. 880 ms [p = 0.03] and 393 ms vs. 400 ms  
[p < 0.001], respectively).
Conclusions: Initial and indicative value of atrial fibrillation and atrial flutter detection in KM is 
comparable to results achieved in standard ECG. KM was superior in detection of sinus rhythm than 
eye-ball evaluation of 12-lead ECG. Though, the PQ and QT intervals were shorter in KM as compared 
to 12-lead ECG. Clinical value needs to be verified in large studies, though. (Cardiol J XXXX; XX, X: 
xx–xx)
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Introduction
Increasing versatility of mobile devices pro-
vides an opportunity to implement them in the 
diagnosis and follow-up of patients with cardio-
vascular disorders. Kardia Mobile (KM) (AliveCor 
Inc., San Francisco, CA, USA) is a portable, mo-
bile, connected electrocardiogram (ECG) device 
available to iOS and Android platform smartphone 
owners. It consists of a small device with two 
conducting plates that wirelessly connect with 
a smartphone, and an application installed on user 
smartphones. It enables one-lead ECG recording 
e.g. in cases of the onset of unsettling symptoms 
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(palpitations, chest pain, dyspnea, and others). KM 
was designed to detect periods of atrial fibrillation 
(AF), which, if confirmed by the Food and Drug 
Administration (FDA)-approved algorithm, can 
then be reported to the physician responsible for 
the follow-up of a given patient. The accessibility 
of KM has prompted the present evaluation of its 
usefulness in comparison with 12-lead ECG record-
ings in assessing the underlying rhythm and basic 
ECG parameters (PQ, RR, and QT intervals). The 
aim herein was to establish protocol, according to 
evidence-based medicine, on whether it has accept-
able sensitivity and specificity, and thus, useful and 
reliable for medical professionals.
Methods
Recruitment
A total of 100 consecutive patients of mean age 
68 ± 14.2, with male subjects constituting 66% of 
the group of a tertiary cardiovascular care center 
were included in the study. Baseline characteristics 
can be found in the Table 1.
The patients were admitted to hospital elec-
tive diagnostic and treatment procedures for vari-
ous cardiac conditions (arrhythmias, conduction 
disorders, stable coronary disease, hypertension 
and others). The group consisted of 100 patients 
consecutively admitted to the documented center 
between July 1st and July 31st 2015. The inclusion 
criterium was undergoing regular 12-lead ECG due 
to standard diagnosis on admission in stable state. 
All patients who urgently needed medical care were 
excluded. Upon referral for a 12-lead ECG, each 
patient was asked to provide informed consent for 
additional KM ECG recording. All patients agreed 
to take part in the study. The subjects’ clinical state 
was stable at the time of ECG recording. First a 
12-lead ECG was performed and KM ECG was 
recorded directly after this procedure. Two techni-
cians were responsible for 12-lead ECG measure-
ments and one physician to record KM ECGs.
ECG assessment
Both 12-lead and KM ECG records were ana-
lyzed by three independent teams comprised of two 
cardiologists each. ECG interpretation was carried 
out according to a previously elaborated online 
form, consistent with the Polish ECG Description 
Guidelines [1], which required assessment of the 
following: ECG quality (good, acceptable, poor), 
rhythm (sinus rhythm, AF, atrial flutter [AFl] 
or pacemaker rhythm), presence of pathological 
Q wave as well as PQ, RR and QT measurements. 
Table 1. Patient characteristics.
Baseline demographics N (%) or 
mean ± SD
Gender [male] 66 (66.0%)
Age [years] 68.0 ± 14.2
Body mass [kg] 80.7 ±15.9
Height [m] 1.7 ± 0.1
Body mass index 28.0 ± 4.8
Medical history
Nicotinism (history): 40 (43.5%)
Nicotinism active 9 (9.8%)
Packyears cumulative 33.4 ± 22.5
Diabetes mellitus 20 (20.4%)
Hypertension 67 (68.4%)
Dyslipidemia 45 (46.4%)
Chronic kidney disease: 32 (32.7%)
CKD G2 2 (2.0%)
CKD G3 23 (23.5%)
CKD G4 7 (7.1%)
CKD G5 1 (1.0%)
Thyroid dysfunction: 18 (18.4%)
Hypothyroidism 9 (9.18%)
Hyperthyroidism 9 (9.18%)
COPD: 6 (6.12%)
Parkinson’s disease 1 (1.02%)
Cerebrovascular disease 17 (17.35%)
Peripheral artery disease 12 (12.24%)
Cardiovascular history
Stable angina (angina pectoris) 46 (47.4%)
ACS (admission) 15 (15.31%)
Myocardial infarction (history) 25 (25.5%)
PCI/CABG (history) 27 (27.6%)
Cardiac surgery (other than CABG) 3 (3.1%)
Heart failure: 43 (43.9%)
NYHA II 28 (28.6%)
NYHA III 9 (9.2%)
NYHA IV 6 (6.1%)
LVEF [%] 49 ± 14
Atrial fibrillation: 34 (34.7%)
Paroxysmal 16 (16.33%)
Persistent 4 (4.1%)
Chronic 14 (14.3%)
CIED implanted 34 (34.7%)
Pacemaker: 24 (24.5%)
AAI 2 (2.0%)
VVI 7 (7.1%)
DDD 15 (15.3%)
ICD 5 (5.1%)
CRT 5 (5.1%)
Ablation 6 (6.1%)
ACS — acute coronary syndrome at the time of admission; CABG —  
coronary artery bypass grafting; CIED — cardiac implantable 
electronic device; CKD — chronic kidney disease (G2-G5 — CKD 
stages); COPD — chronic obstructive pulmonary disease; CRT —  
cardiac resynchronization therapy device; ICD — implantable 
cardioverter-defibrillator; LVEF — left ventricular ejection fraction 
measured during the hospitalization; NYHA — New York Heart  
Association functional classification; PCI — percutaneous coronary 
intervention
2 www.cardiologyjournal.org
Cardiology Journal XXXX, Vol. XX, No. X
In order to avoid cognitive and measurement bias, 
all KM ECG records were printed out in 1:1 ratio 
and assessed in paper-based form. A database com-
prised of answers provided by the teams. The study 
protocol and informed consent form was approved 
by the local bioethics committee.
Statistical analysis
The data were analyzed using adequate statis-
tical tests with the aim of looking for agreement 
between the two diagnostic methods. In case of 
disagreement, ECGs were reevaluated by a data 
committee consisting of three ECG experts, who 
then provided a final report. 
Continuous variables were expressed as mean 
± standard deviation, and categorical variables 
were stored as number of cases or percentage. 
The Student t-test was used for comparison of 
continuous variables, while categorical variables 
were compared using the c2 test or the Fisher 
exact test, as appropriate among the groups. All 
tests were two-tailed and a p-value of < 0.05 was 
considered significant. All statistical analyses were 
performed using MedCalc 17.6 software (MedCalc 
Software, Ostend, Belgium).
Results
A total of 99 KM ECGs and 100 12-lead ECGs 
were analyzed. In 1 patient, KM recording was not 
possible due to an underlying condition (tremors 
secondary to Parkinson’s disease). Comparison 
of KM ECGs and 12-lead ECGs revealed that the 
overall quality of the latter was superior (6 vs. 0 
— poor, 41 vs. 1 — acceptable, 52 vs. 99 — good, 
p < 0.001). Effectiveness evaluation of KM with 
regards to rhythm determination was performed 
by comparing it with 12-lead ECG interpretation. 
Sensitivity and specificity were tested for the fol-
lowing rhythms:
 — sinus rhythm — 98.4% and 74.2% (p = 0.02);
 — atrial fibrillation — 92.8% and 100% (p = 0.32);
 — atrial flutter — 100% and 100% (p value not 
applicable);
 — pacemaker rhythm — 53.6% and 100% (p = 
0.008).
Sensitivity and specificity of KM for patho-
logical Q wave detection was 20.6% and 93.7%, 
respectively (p < 0.001). Mean PQ, RR and QT 
measurements in KM ECGs and 12-lead ECGs 
were as follows:
 — PQ — 160 ms vs. 180 ms (p < 0.001);
 — RR — 853 ms vs. 880 ms (p = 0.03);
 — QT — 393 ms vs. 400 ms (p < 0.001).
Discussion
Principal results
With regard to the fact that many life-threaten-
ing arrhythmias are non-sustained and occur infre-
quently, it is justified to search for relatively cheap 
solutions giving the patient a chance to record an 
ECG at the onset of unsettling symptoms. Apart 
from the conventional, clinically-approved meth-
ods, recent years have brought a few breakthroughs 
regarding smartphone-dependent devices enabling 
such a procedure. Versatility of mobile phones and 
general access to the Internet has created the pos-
sibility to remotely provide the practitioners with 
information of possible clinical significance, and 
thus enable them to react in case of an emergency.
Although reliability of such solutions has not 
yet been thoroughly investigated in randomized 
clinical trials, some data suggests good compli-
ance and improved patient management. The most 
obvious application of smartphone-compatible 
ECG devices that has been brought up is the pos-
sibility of screening for patients with paroxysmal 
AF especially for those who need antithrombotic 
therapy [2–4]. 
The present study confirmed that KM, despite 
its simplicity, provides a record of sufficient quality 
to diagnose periods of AF. KM has also proven to 
be reliable while supervising QTc period in patients 
on dofetilide [5] and in pediatric patients with 
various arrhythmic disorders [6]. In contrast study 
revealed that QT measurements in KM ECGs are 
shorter on average by an average of 7 ms, whereas 
PQ intervals tend to be shorter by as much as 
20 ms (more than a 10% difference compared to 
the conventional ECG). This phenomenon has not 
as yet been described in the literature available 
and may potentially mimic arrhythmia, e.g. pre-
excitation syndrome in extreme cases or conceal 
atrioventricular blocks, but this tendency was not 
confirmed in this study.
Extremely high sensitivity compared to rela-
tively lower specificity of KM detection of sinus 
rhythm is a characteristic that potentially was 
previously heralded by Narasimha et al. [7] who 
reported that nearly one third of patients declaring 
alarming symptoms while the ECG was assessed 
normal by the algorithm. One in four patients in 
our population ascribed by KM to sinus rhythm 
category should in fact have been described differ-
ently. Based on the construction of the KM device, 
it is not surprising that it has low sensitivity in de-
tecting pacemaker rhythm, this supports Desteghe 
et al. [8] findings and recommendations.
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According to available research, this is the 
first study to investigate and compare selected 
parameters in KM records and conventional 12-
lead ECGs. New studies, currently with protocols 
available [9, 10] will shortly verify the usefulness 
of the method and the present findings.
New studies being currently conducted can 
be also groundbreaking in respect to ischemia 
detection, and thus rapid detection of myocardial 
infarction in symptomatic patients [11, 12]. 
Limitations of the study
Despite the prospective design of this study 
there are some important limitations. Firstly, this 
is a single center study. Secondly, ECG interpre-
tation is subjective and thus there may have been 
certain discrepancies. There were only three teams 
analyzing the records and assessments of ECG 
quality were subjective according to their expertise 
which may somehow bias this study. Furthermore, 
a group of stable subjects were analyzed, which 
made it impossible to verify KM applicability for 
cases of acute cardiac events. Finally, the number 
of patients included in the study is relatively small 
and a larger group would enable more reliable 
conclusions.
Comparison with prior work
The onset of certain clinical symptoms such as 
syncope, palpitations and chest pain may indicate 
an underlying cardiovascular etiology. Among oth-
ers, paroxysmal arrhythmias are a potential culprit. 
Long-term ECG monitoring has proven to be an 
important measure in diagnosing elusive periods 
of AF, supraventricular arrhythmias and ventricular 
arrhythmias [4, 13, 14]. To confirm the relation 
between the symptoms and arrhythmias, the 
European Society of Cardiology (ESC) guidelines 
recommend continuous or intermittent ambula-
tory ECG monitoring. This procedure also makes 
it possible to verify if the arrhythmic events are 
secondary to an ischemic heart disease [13, 15]. 
An appropriate, long-term ECG screening may 
warn the clinician of a series of potential adverse 
clinical events. Sudden cardiac death (SCD), one 
of the leading direct causes of mortality in the 
western world, whether secondary to ischemic 
heart disease or to congenital malfunctioning of the 
electrical conductance system of the heart, could 
be in many cases prevented by pharmacotherapy 
or implantable cardioverter-defibrillator (ICD) 
implantation [13]. Furthermore, paroxysmal AF 
is a proven risk factor for stroke, another impor-
tant cause of mortality and disability in developed 
societies [16–18]. Up until recently it has been 
estimated that even 20–40% of ischemic strokes 
remain idiopathic, but some clinical trials have 
shown a higher prevalence of paroxysmal AF 
detectable on a long-term ECG analysis in com-
parison with a standard 24 h Holter monitoring 
in this group of patients [19–22]. The KM system 
was assessed in a study conducted by Halcox et al. 
[22] in a randomized control trial (REHEARSE-AF 
study) in a group of patients older than 65 years 
with an elevated risk of cerebral thromboembolism 
(CHA2DS2-VASc score ≥ 2). The results presented 
a proactive approach of regular weekly iECG 
monitoring with the use of KM system may not 
only be preventive in a medical sense, but also 
cost-effective in AF detection. This observation 
opens the discussion over the possibility of a more 
routine implementation of KM in clinical practice 
to remotely monitor QT periods. 
Rapid diagnosis of AF can prevent cerebral 
thromboembolic events, and according to recent 
publication by Rattanawong et al. [23], it can also 
reduce overall SCD rate. As AF has been reported 
to provide higher risk of SCD than other associated 
factors, such as previous myocardial infarction, 
heart failure or coronary artery disease, preven-
tive measures using quick and easy diagnostic 
tools such as KM could be undertaken to avoid 
unnecessary hospitalizations and reduce mortality 
in this subgroup.
Another important feature of every telemoni-
toring device that needs to be discussed is its avail-
ability. Surveys gathered from subjects enrolled in 
the SPEAR trial showed a high level of satisfaction 
and willingness to continue implementing KM 
ECG testing in the future [4]. Furthermore, all the 
patients that took part in the present study showed 
a positive attitude towards KM as well. Such at-
titudes have also been observed in a recent study 
by Halcox et al. [22] with patients of advanced age 
being enthusiastic about such methods. 
Patients can be subjected to more personalized 
care due to the possibility of remote transmission 
of their ECG records to their physician. In recent 
years a proactive attitude was positively tested 
by Klein-Wiele et al. [24], who provided data of 
successful cooperation between patients, general 
practitioners and cardiologists. The KM device 
could be part of a cross-sector telemetric network 
with rapid response to a patients’ worsening state 
of health by qualified professionals.
Apart from clinical reliability, it also needs to 
be verified whether smartphone-based ECG con-
trols are not an excessive financial burden for the 
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health care system. Initial data suggest that there is 
no long-term difference in cost-efficiency between 
conventional monitoring and smartphone supervi-
sion, while patient self-awareness seems to benefit 
from remote self-controls [25]. Nevertheless, this 
is still a matter of debate as the information at hand 
are scarce.
Kardia Mobile aside, smartphone-based ECG 
device market constantly expands, offering new 
solutions for mobile phones with Android operat-
ing systems [26], or enabling a context-aware ECG 
monitoring [27]. Moreover, specifically oriented 
systems such as Remote Cardio Control (RCC) 
designed to diagnose signs of myocardial infarction, 
continue to be created [28]. It can be conceived that 
in the following years devices encompassing those 
standards of diagnostic procedures will become a 
part of routine approach.
It should be also noted that the number of 
reports considering mobile ECG record is rising. 
Apart from arrhythmias considered in this study, 
there is a possibility to record and diagnose other 
heart rhythm disturbances, including atrioven-
tricular block [29]. This poses even greater area 
for implementation of these devices into general 
practitioner practice.
Conclusions
The usefulness of KM is unquestionable 
in the prevention and rapid detection of AF and 
AFls in a standard comparable to the conventional 
method, namely 12-lead ECG. Applying this novel 
device to routine diagnostics is rather preemptive, 
as discrepancies in sensitivity of the algorithm 
may present a possible misinterpretation of the 
outcome. The clinical need for an easy-to-use 
mobile ECG is immense, however it is concluded 
herein, that further studies are needed to confirm 
diagnostic value.
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